STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and more

Coverage, in order

1. 17d ago
   
   first WSJ Health mainstream

   Roche Targets Emerging Oncology Market With New Lung-Cancer Drug

   The drugmaker expects a pill it is developing to become the new standard treatment for an advanced form of lung cancer, and the company’s first shot at an emerging field within the oncology market.

2. 16d ago
   
   STAT News indie study

   STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and more

   Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance. But what can you do? The world, such as it is, continues to rotate. To…

3. 16d ago
   
   STAT News indie study

   STAT+: Roche gets a lung cancer win with its KRAS drug divarasib

   You’re reading our ESMO in 30 Seconds newsletter. Sign up here to get updates from future major European cancer conferences in your inbox. We’ve made it. Here’s our last newsletter from this year’s European Society for Medical Oncology meeting. But before we bust out of this convention center for…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.